Date Title Description PDF
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download
22 Jun 2021 On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Download
29 Apr 2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.     Download
12 Apr 2021 On business and financial situation The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. Download
02 Mar 2021 On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download

Pages

Date Title Description PDF
26 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 19 January and 25 January 2024 Download
19 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 12 January and 18 January 2024 Download
12 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 5 January and 11 January 2024 Download
05 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 29 December 2023 and 4 January 2024 Download
29 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 22 December and 28 December 2023 Download

Pages

Date Title Description PDF
05 Jul 2019 R&D: new licenses, patents and registered trademarks ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia. Download
02 Jul 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the second quarter of 2019 Download
26 Jun 2019 Información sobre dividendos The Company informs about the dividends payment Download
12 Jun 2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its General Shareholders Meeting Download
08 May 2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its 2019 General Shareholders Meeting Download

Pages